Goodbye needles, hello nanopatch

Based in Brisbane this medical device company for vaccine delivery is using a game-changing micro-needle technology (NanopatchTM) developed at the University of Queensland.

Prof. Mark Kendall who heads the research team developing the Nanopatch received the Translational Research Excellence Commercialisation Award for the Nanopatch and Vaxxas was a finalist in
the Enterprize Business Plan competition in 2010.

Vaxxas has attracted $15 million of investment to continue development of the Nanopatch and take it to clinical trials. Investors, led by OneVentures, include Brandon Capital, the Medical Research
Commercialisation Fund (MRCF) and US-based HealthCare Ventures.

Related Stories
11.12.2015
Logo-Hazer

Hazer Group live on ASX

Hazer Group was established in 2010 from technology developed at UWA to produce clean hydrogen and high-grade synthetic graphite from natural gas and iron ore. Its development depended on AMMRF microscopy @ UWA. They have announced the successful ...

24.09.2015
burn victim

Fast-tracking elastin to market

Prof. Tony Weiss from the University of Sydney in conjunction with Elastagen Pty Ltd has been awarded a $1million Translation Award from the Wellcome Trust to fast track their elastin-based synthetic skin to clinical trials. They will refine and ...

02.10.2014
NanopatchInSkin

Nanopatch to tackle polio

The World Health Organization (WHO) is to provide funding to spin-out company, Vaxxas, so it can develop the NanopatchTM for polio vaccination. WHO will fund pre-clinical studies and the development of good manufacturing practices. Following the ...

MORE NEWS...